AR050043A1 - Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares - Google Patents
Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovascularesInfo
- Publication number
- AR050043A1 AR050043A1 ARP050103198A ARP050103198A AR050043A1 AR 050043 A1 AR050043 A1 AR 050043A1 AR P050103198 A ARP050103198 A AR P050103198A AR P050103198 A ARP050103198 A AR P050103198A AR 050043 A1 AR050043 A1 AR 050043A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkoxy
- inhibitor
- pharmaceutical composition
- renin inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Método para mejorar la biodisponibilidad de un inhibidor de renina, de preferencia de un derivado de amida del ácido delta-amino-gamma-hidroxi-omega-aril-alcanoico, cuyo método comprende co-administrar a un mamífero, en especial a un ser humano, que necesite dicho tratamiento, una combinacion de un inhibidor de renina, o una sal farmacéuticamente aceptable del mismo, y un inhibidor de proteínas de efusion, como por ejemplo, PSC 833 (3-ceto-[Bntl]-[Val2]-ciclosporina). Reivindicacion 4: Un método de acuerdo con la reivindicacion 3, en donde el derivado de amida del ácido delta-amino-gamma-hidroxi-omega-aril-alcanoico tiene la formula (1), en donde R1 es alcoxilo de 1 a 4 átomos de carbono-alcoxilo de 1 a 4 átomos de carbono o alcoxilo de 1 a 4 átomos de carbono-alquilo de 1 a 4 átomos de carbono; R2 es alquilo de 1 a 4 átomos de carbono o alcoxilo de 1 a 4 átomos de carbono; y R3 y R4 son independientemente alquilo de 1 a 4 átomos de carbono ramificado; o una sal farmacéuticamente aceptable del mismo. Reivindicacion 8: Una composicion farmacéutica, la cual comprende una cantidad terapéuticamente efectiva de un inhibidor de renina en combinacion con un inhibidor de proteínas de efusion, estando este inhibidor de proteínas de efusion presente en una cantidad tal que, enseguida de la administracion, se mejora la biodisponibilidad de un inhibidor de renina por cuando menos el 5%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59870004P | 2004-08-03 | 2004-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050043A1 true AR050043A1 (es) | 2006-09-20 |
Family
ID=35056890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103198A AR050043A1 (es) | 2004-08-03 | 2005-08-01 | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7709532B2 (es) |
| EP (2) | EP1776099B1 (es) |
| JP (1) | JP5134366B2 (es) |
| KR (1) | KR20070040384A (es) |
| CN (1) | CN1993116B (es) |
| AR (1) | AR050043A1 (es) |
| AT (1) | ATE449601T1 (es) |
| AU (1) | AU2005268844B2 (es) |
| BR (1) | BRPI0514021A (es) |
| CA (1) | CA2572743C (es) |
| CY (1) | CY1109826T1 (es) |
| DE (1) | DE602005017905D1 (es) |
| DK (1) | DK1776099T3 (es) |
| EC (1) | ECSP077169A (es) |
| ES (1) | ES2335597T3 (es) |
| HR (1) | HRP20100064T1 (es) |
| IL (1) | IL180678A (es) |
| MA (1) | MA28821B1 (es) |
| MX (1) | MX2007001339A (es) |
| MY (1) | MY142180A (es) |
| NO (1) | NO20071142L (es) |
| NZ (1) | NZ552903A (es) |
| PE (1) | PE20060416A1 (es) |
| PL (1) | PL1776099T3 (es) |
| PT (1) | PT1776099E (es) |
| RU (1) | RU2404758C2 (es) |
| SI (1) | SI1776099T1 (es) |
| TN (1) | TNSN07038A1 (es) |
| TW (1) | TW200616610A (es) |
| WO (1) | WO2006013094A1 (es) |
| ZA (1) | ZA200610639B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
| EP1927350A1 (en) * | 2006-11-24 | 2008-06-04 | Novartis AG | Methods for improving bioavailability of a renin inhibitor |
| WO2011012319A1 (en) | 2009-07-31 | 2011-02-03 | Sandoz Ag | Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method |
| WO2012010651A2 (en) | 2010-07-23 | 2012-01-26 | Sandoz Ag | Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method |
| WO2014168255A1 (ja) * | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 巨核球の成熟化促進物質 |
| WO2015035218A1 (en) * | 2013-09-05 | 2015-03-12 | Howard University | Method of increasing the bioavailability of an hiv drug |
| JP6029621B2 (ja) * | 2014-07-14 | 2016-11-24 | ヤマサ醤油株式会社 | 血漿レニン活性の測定法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108499A (en) | 1993-02-04 | 2000-02-29 | Lilly Co Eli | Mammalian influx peptide transporter |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| JPH11507356A (ja) | 1995-06-07 | 1999-06-29 | アブマックス，インコーポレイティド | 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用 |
| BR0015149A (pt) * | 1999-10-27 | 2002-10-29 | Baker Norton Pharma | Método e composições para administração de taxanos oralmente a pacientes humanos |
| US20020142950A1 (en) * | 2000-02-11 | 2002-10-03 | Hayward Neil J. | Methods for enhancing the bioavailability of a drug |
| WO2001092468A2 (en) * | 2000-05-31 | 2001-12-06 | Rutgers, The State University Of New Jersey | Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| GB0113663D0 (en) * | 2001-06-05 | 2001-07-25 | Novartis Ag | Use of organic compounds |
| KR20040066177A (ko) | 2001-12-19 | 2004-07-23 | 알자 코포레이션 | 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태 |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| WO2003092729A1 (de) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer |
| PT1517682E (pt) * | 2002-06-28 | 2007-02-28 | Speedel Pharma Ag | Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo |
| TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
-
2005
- 2005-08-01 PE PE2005000883A patent/PE20060416A1/es not_active Application Discontinuation
- 2005-08-01 AR ARP050103198A patent/AR050043A1/es not_active Application Discontinuation
- 2005-08-02 JP JP2007524264A patent/JP5134366B2/ja not_active Expired - Fee Related
- 2005-08-02 MX MX2007001339A patent/MX2007001339A/es active IP Right Grant
- 2005-08-02 NZ NZ552903A patent/NZ552903A/en not_active IP Right Cessation
- 2005-08-02 CA CA2572743A patent/CA2572743C/en not_active Expired - Fee Related
- 2005-08-02 PL PL05769973T patent/PL1776099T3/pl unknown
- 2005-08-02 EP EP05769973A patent/EP1776099B1/en active Active
- 2005-08-02 US US11/572,471 patent/US7709532B2/en not_active Expired - Fee Related
- 2005-08-02 WO PCT/EP2005/008369 patent/WO2006013094A1/en active Application Filing
- 2005-08-02 SI SI200530915T patent/SI1776099T1/sl unknown
- 2005-08-02 DK DK05769973.8T patent/DK1776099T3/da active
- 2005-08-02 KR KR1020077002718A patent/KR20070040384A/ko active IP Right Grant
- 2005-08-02 AU AU2005268844A patent/AU2005268844B2/en not_active Ceased
- 2005-08-02 PT PT05769973T patent/PT1776099E/pt unknown
- 2005-08-02 BR BRPI0514021-8A patent/BRPI0514021A/pt not_active IP Right Cessation
- 2005-08-02 CN CN2005800261744A patent/CN1993116B/zh not_active Expired - Fee Related
- 2005-08-02 DE DE602005017905T patent/DE602005017905D1/de active Active
- 2005-08-02 TW TW094126194A patent/TW200616610A/zh unknown
- 2005-08-02 MY MYPI20053584A patent/MY142180A/en unknown
- 2005-08-02 AT AT05769973T patent/ATE449601T1/de active
- 2005-08-02 EP EP09014648A patent/EP2191823A1/en not_active Withdrawn
- 2005-08-02 ES ES05769973T patent/ES2335597T3/es active Active
- 2005-08-02 RU RU2007107850/15A patent/RU2404758C2/ru not_active IP Right Cessation
-
2006
- 2006-12-18 ZA ZA200610639A patent/ZA200610639B/en unknown
-
2007
- 2007-01-11 IL IL180678A patent/IL180678A/en not_active IP Right Cessation
- 2007-01-15 EC EC2007007169A patent/ECSP077169A/es unknown
- 2007-02-02 TN TNP2007000038A patent/TNSN07038A1/en unknown
- 2007-02-22 MA MA29709A patent/MA28821B1/fr unknown
- 2007-02-28 NO NO20071142A patent/NO20071142L/no not_active Application Discontinuation
-
2010
- 2010-01-05 CY CY20101100019T patent/CY1109826T1/el unknown
- 2010-02-02 HR HR20100064T patent/HRP20100064T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares | |
| AR062792A1 (es) | Derivados azetidinona y metodos de uso de estos | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
| MX2010006209A (es) | Derivados de quinoxalinilo. | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| PH12012500765A1 (en) | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | |
| MY155851A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
| AR050463A1 (es) | Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer. | |
| UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
| MX2010006518A (es) | Inhibidores de serina proteasa de hepatitis c de oximil macrociclica. | |
| MX2010008109A (es) | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). | |
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| CO6612246A2 (es) | Derivados de 2-arilimidazol como inhibidores de enzima pde10a | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| MX2010008108A (es) | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. | |
| AR068343A1 (es) | Dipsipeptidos ciclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |